# Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

> **NCT00782470** · — · COMPLETED · sponsor: **Bayer** · enrollment: 38 (actual)

## Conditions studied

- Hematologic Disease
- Blood Coagulation Disorders

## Interventions

- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)
- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)
- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)

## Key facts

- **NCT ID:** NCT00782470
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782470, "Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00782470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*